Enlivex Therapeutics Ltd. (ENLV)
NASDAQ: ENLV · Real-Time Price · USD
0.8600
0.00 (0.00%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Enlivex Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Enlivex Therapeutics stock have an average target of 10, with a low estimate of 7.00 and a high estimate of 13. The average target predicts an increase of 1,062.79% from the current stock price of 0.86.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Enlivex Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +1,411.63% | Apr 3, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $7 | Strong Buy | Maintains | $6 → $7 | +713.95% | Mar 24, 2025 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +1,411.63% | Mar 3, 2025 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +1,411.63% | Feb 7, 2025 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +1,411.63% | Dec 11, 2024 |
Financial Forecast
Revenue This Year
n/a
from 102.78M
Revenue Next Year
n/a
EPS This Year
-0.60
from -0.73
EPS Next Year
-0.60
from -0.60
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | ||
Avg | n/a | n/a | n/a | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.61 | -0.62 | -0.82 | ||
Avg | -0.60 | -0.60 | -0.80 | ||
Low | -0.58 | -0.58 | -0.76 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.